- Home
- PSNL vs CNTB Comparison
PSNL vs CNTB Comparison
Compare PSNL & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | CNTB |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 140.4M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PSNL | CNTB |
|---|---|---|
| Price | $16.19 | $1.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $12.20 | $8.67 |
| AVG Volume (30 Days) | ★ 2.7M | 1.7M |
| Earning Date | 05-07-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,648,000.00 | $64,000.00 |
| Revenue This Year | $15.34 | N/A |
| Revenue Next Year | $41.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.96 | $1.06 |
| 52 Week High | $18.89 | $3.82 |
Technical Indicators
Market Signals| Indicator | PSNL | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 52.56 | 32.35 |
| Support Level | $7.62 | N/A |
| Resistance Level | $16.39 | $2.78 |
| Average True Range (ATR) | 0.49 | 0.26 |
| MACD | -0.19 | -0.10 |
| Stochastic Oscillator | 17.12 | 10.65 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.